Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 131   

Articles published

NVO 44.56 -1.36 (-2.96%)
price chart
Novo Nordisk To Go Ahead With Russian Investment
The world's largest insulin-maker, Novo Nordisk A/S (ADR) (NYSE:NVO) is going ahead with its investment plans for Russia, even after the ruble's drastic fall.
First Call Rating Update on Novo Nordisk A/S (ADR)  Stafford Daily
Stocks Underperform for the Week: Novo Nordisk A/S , Cablevision Systems Corp  Ashburn Daily
Latest Updates on Novo Nordisk A/S (ADR) (NYSE:NVO)
The injectable drug is the second obesity treatment to be approved by the FDA this year; the first obesity-related treatment, approved in September, was Contrave, an oral medicine by Orexigen Therapeutics Inc. (NASDAQ:OREX).
Novo Nordisk (NVO) Searching For A New CEO  Bidness ETC
Related articles »  
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Commerbank Rating Disclosure on Novo Nordisk A/S (ADR)
Equity analysts at the Brokerage firm Commerbank downgrades its rating on Novo Nordisk A/S (ADR) (NYSE:NVO). The rating major has initiated the coverage with an hold rating on the shares.
Novo Nordisk A/S (ADR) Analyst Rating Update  Wall Street Pulse
Novo Nordisk (NVO) Wins FDA Nod For Weight-Loss Injection
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Wednesday that the US Food and Drug Administration (FDA) has approved its experimental weight-loss injection, Saxenda, to treat obesity in adults.
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
Novo Nordisk And Eli Lilly Battling To Win GLP-1 Drug Market
Novo Nordisk A/S (ADR) (NVO) is currently leading the GLP-1 agonist space with its injectable drug Victoza, which was launched in 2009.
Related articles »  
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate ...
Novo Nordisk A/S (ADR) (NYSE:NVO) also kept its spot in Mr. Simons' list. The $189 billion market cap healthcare company witnessed a 5% boost in the fund's exposure between April and June.
Novo Nordisk's (NVO) Diabetes Drug Victoza Receives Positive Review By CHMP
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Friday that its key drug Victoza has received positive reviews from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes ...
Related articles »  
Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis ...
Novo Nordisk A/S (NYSE: NVO) is the undisputed global leader in the diabetes market. The company's impressive product portfolio is home to five of the world's 10 best-selling diabetes medications.
Related articles »